Tandem Diabetes Care Inc
(STU:TD5A)
€
29.15
-1.65 (-5.36%)
Market Cap: 1.92 Bil
Enterprise Value: 1.92 Bil
PE Ratio: 0
PB Ratio: 8.66
GF Score: 82/100 
Tandem Diabetes Care Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2023 / 03:30PM GMT
Release Date Price:
€17.99
(+3.99%)
Matthew Oliver O;Brien
Piper Sandler & Co., Research Division - MD & Senior Research Analyst
' -
Hi, everybody, thanks for joining us. Matt O'Brien, I cover Med-Tech here at Piper. Very excited to have the Tandem Diabetes management team here with us. From the company, we've got John, who's the CEO, and then Susan, who's the Head of IR and Corporate Communications. Leigh can't be here because of a family issue, unfortunately, which is much more important than talking to Matthew O'Brien. I can assure you of that. But thank you, so much for coming. I do appreciate it.
John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director
Yes.
Questions & Answers
Matthew Oliver O;Brien;John F. Sheridan
Piper Sandler & Co., Research Division - MD & Senior Research Analyst;Tandem Diabetes Care, Inc. -
' -
I guess -- so sick of talking about these GLPs, but let's start with that, first of all. Type 1 penetration, about 40% today.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers